Electrogenics Laboratories Limited

The next generation MOSkin dosimeter is the only medical radiation sensor technology in the world that accurately measures individual radiation doses and dose rates, in real time, at precisely defined and reproducible skin tissue and organ depth for the global $35 billion radiotherapy for cancer treatment, angiography equipment and CT and Xray scan markets. Electrogenics Laboratories Ltd (ELL), was formed in 2019 to commercialise this breakthrough, patented technology developed by the Centre for Medical Radiation Physics (CMRP), University of Wollongong (UOW), Australia. It has been fully tested and proven with over $8 million of grant funding in over 20 hospitals and clinics including Australia, Brazil, Italy, Malaysia and China. The ELL senior management and support staff team provide extensive experience in advanced technology product development and international business development to rapidly drive MOSkin to full global commercialisation and distribution. Distinguished Professor Anatoly Rozenfeld, Professor Michael Lerch, and Associate Professor Marco Petasecca from UOW are ELL’s scientific advisors. Australian development partners including Genesys Electronics Design and Design & Industry. ELL’s goal is to become the world leader in the development and provision of cutting edge, next generation radiation dosimetry solutions. T